{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:05:32Z","timestamp":1792638332093,"version":"4.5.0"},"reference-count":304,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41568-026-00918-y","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:23:08Z","timestamp":1776183788000},"page":"415-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The versatile interplay between steatotic liver disease and liver cancer"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-2134","authenticated-orcid":false,"given":"Mohammad","family":"Rahbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-9541","authenticated-orcid":false,"given":"Albert","family":"Gris-Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-9648","authenticated-orcid":false,"given":"Pierluigi","family":"Ramadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisar P.","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Llovet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-2274","authenticated-orcid":false,"given":"Mathias","family":"Heikenw\u00e4lder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"918_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M., Francque, S., Tsochatzis, E. A. & Krag, A. Steatotic liver disease. Lancet 404, 1761\u20131778 (2024).","journal-title":"Lancet"},{"key":"918_CR2","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jhep.2021.01.045","volume":"74","author":"R Liebe","year":"2021","unstructured":"Liebe, R. et al. Diagnosis and management of secondary causes of steatohepatitis. J. Hepatol. 74, 1455\u20131471 (2021).","journal-title":"J. Hepatol."},{"key":"918_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong, V. W., Ekstedt, M., Wong, G. L. & Hagstrom, H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J. Hepatol. 79, 842\u2013852 (2023).","journal-title":"J. Hepatol."},{"key":"918_CR4","doi-asserted-by":"publisher","first-page":"100784","DOI":"10.1016\/j.jhepr.2023.100784","volume":"5","author":"N Reggidori","year":"2023","unstructured":"Reggidori, N. et al. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs. JHEP Rep. 5, 100784 (2023).","journal-title":"JHEP Rep."},{"key":"918_CR5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2017.01.010","volume":"66","author":"A Moeini","year":"2017","unstructured":"Moeini, A. et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J. Hepatol. 66, 952\u2013961 (2017).","journal-title":"J. Hepatol."},{"key":"918_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cgh.2010.06.027","volume":"8","author":"R Loomba","year":"2010","unstructured":"Loomba, R. et al. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin. Gastroenterol. Hepatol. 8, 891\u2013898 (2010).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"918_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000450","volume":"8","author":"M Babuta","year":"2024","unstructured":"Babuta, M. et al. A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis. Hepatol. Commun. 8, e0450 (2024).","journal-title":"Hepatol. Commun."},{"key":"918_CR8","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"918_CR9","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"918_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411\u2013428 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.medj.2021.03.002","volume":"2","author":"S Gallage","year":"2021","unstructured":"Gallage, S. et al. The therapeutic landscape of hepatocellular carcinoma. Med 2, 505\u2013552 (2021).","journal-title":"Med"},{"key":"918_CR12","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686\u2013690 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2023.05.022","volume":"377","author":"S Gonzalez-Palacios","year":"2023","unstructured":"Gonzalez-Palacios, S. et al. Increased ultra-processed food consumption is associated with worsening of cardiometabolic risk factors in adults with metabolic syndrome: longitudinal analysis from a randomized trial. Atherosclerosis 377, 12\u201323 (2023).","journal-title":"Atherosclerosis"},{"key":"918_CR14","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMra2207599","volume":"387","author":"R Bataller","year":"2022","unstructured":"Bataller, R., Arab, J. P. & Shah, V. H. Alcohol-associated hepatitis. N. Engl. J. Med. 387, 2436\u20132448 (2022).","journal-title":"N. Engl. J. Med."},{"key":"918_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra, F. & Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 68, 280\u2013295 (2018).","journal-title":"J. Hepatol."},{"key":"918_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","volume":"19","author":"M Ringelhan","year":"2018","unstructured":"Ringelhan, M., Pfister, D., O\u2019Connor, T., Pikarsky, E. & Heikenwalder, M. The immunology of hepatocellular carcinoma. Nat. Immunol. 19, 222\u2013232 (2018).","journal-title":"Nat. Immunol."},{"key":"918_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","volume":"20","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat. Rev. Gastroenterol. Hepatol. 20, 487\u2013503 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","volume":"54","author":"M Vujkovic","year":"2022","unstructured":"Vujkovic, M. et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat. Genet. 54, 761 (2022).","journal-title":"Nat. Genet."},{"key":"918_CR19","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.31535","volume":"73","author":"TH Schwantes-An","year":"2021","unstructured":"Schwantes-An, T. H. et al. Genome-wide association study and meta-analysis on alcohol-associated liver cirrhosis identifies genetic risk factors. Hepatology 73, 1920\u20131931 (2021).","journal-title":"Hepatology"},{"key":"918_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15691","volume":"8","author":"M Ogrodnik","year":"2017","unstructured":"Ogrodnik, M. et al. Cellular senescence drives age-dependent hepatic steatosis. Nat. Commun. 8, 15691 (2017).","journal-title":"Nat. Commun."},{"key":"918_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1172\/JCI30400","volume":"117","author":"VT Samuel","year":"2007","unstructured":"Samuel, V. T. et al. Inhibition of protein kinase C\u03b5 prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J. Clin. Invest. 117, 739\u2013745 (2007).","journal-title":"J. Clin. Invest."},{"key":"918_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179\u2013185 (2012).","journal-title":"Nature"},{"key":"918_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450\u2013456 (2021).","journal-title":"Nature"},{"key":"918_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3350\/cmh.2019.0012","volume":"26","author":"R Kumar","year":"2020","unstructured":"Kumar, R., Goh, B.-B. G., Kam, J. W., Chang, P. E. & Tan, C. K. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. Clin. Mol. Hepatol. 26, 196\u2013208 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"918_CR25","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","volume":"79","author":"M Li","year":"2024","unstructured":"Li, M. et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology 79, 560\u2013574 (2024).","journal-title":"Hepatology"},{"key":"918_CR26","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-024-00828-8","volume":"5","author":"L Lemaitre","year":"2024","unstructured":"Lemaitre, L. et al. Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease. Nat. Cancer 5, 1534\u20131556 (2024).","journal-title":"Nat. Cancer"},{"key":"918_CR27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41586-025-10036-8","volume":"651","author":"X Li","year":"2026","unstructured":"Li, X. et al. Activated ATF6\u03b1 is a hepatic tumour driver restricting immunosurveillance. Nature 651, 796\u2013807 (2026).","journal-title":"Nature"},{"key":"918_CR28","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.3390\/cancers12113182","volume":"12","author":"S De Lorenzo","year":"2020","unstructured":"De Lorenzo, S. et al. Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role. Cancers 12, 3182 (2020).","journal-title":"Cancers"},{"key":"918_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","volume":"79","author":"E Kotsiliti","year":"2023","unstructured":"Kotsiliti, E. et al. Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signalling. J. Hepatol. 79, 296\u2013313 (2023).","journal-title":"J. Hepatol."},{"key":"918_CR30","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1053\/j.gastro.2023.04.014","volume":"165","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. & Heikenwalder, M. Atezolizumab plus bevacizumab in advanced HCC: efficacy in NASH-specific etiology. Gastroenterology 165, 1308\u20131310 (2023).","journal-title":"Gastroenterology"},{"key":"918_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.7182\/pit2015618","volume":"25","author":"K Schieber","year":"2015","unstructured":"Schieber, K. et al. Self-reports on symptoms of alcohol abuse: liver transplant patients versus rehabilitation therapy patients. Prog. Transpl. 25, 203\u2013209 (2015).","journal-title":"Prog. Transpl."},{"key":"918_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","volume":"77","author":"K Staufer","year":"2022","unstructured":"Staufer, K. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J. Hepatol. 77, 918\u2013930 (2022).","journal-title":"J. Hepatol."},{"key":"918_CR33","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.immuni.2019.09.020","volume":"51","author":"A Christ","year":"2019","unstructured":"Christ, A., Lauterbach, M. & Latz, E. Western diet and the immune system: an inflammatory connection. Immunity 51, 794\u2013811 (2019).","journal-title":"Immunity"},{"key":"918_CR34","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","volume":"6","author":"M Vacca","year":"2024","unstructured":"Vacca, M. et al. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). Nat. Metab. 6, 1178\u20131196 (2024).","journal-title":"Nat. Metab."},{"key":"918_CR35","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.jhep.2015.01.017","volume":"62","author":"AC Piguet","year":"2015","unstructured":"Piguet, A. C. et al. Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. J. Hepatol. 62, 1296\u20131303 (2015).","journal-title":"J. Hepatol."},{"key":"918_CR36","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/gut.2008.162453","volume":"59","author":"J Altamirano","year":"2010","unstructured":"Altamirano, J. & Bataller, R. Cigarette smoking and chronic liver diseases. Gut 59, 1159\u20131162 (2010).","journal-title":"Gut"},{"key":"918_CR37","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1002\/cncr.29577","volume":"121","author":"B Suh","year":"2015","unstructured":"Suh, B. et al. Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index. Cancer 121, 3818\u20133825 (2015).","journal-title":"Cancer"},{"key":"918_CR38","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/jcm12093336","volume":"12","author":"JJ Yoo","year":"2023","unstructured":"Yoo, J. J. et al. Smoking increases the risk of hepatocellular carcinoma and cardiovascular disease in patients with metabolic-associated fatty liver disease. J. Clin. Med. 12, 3336 (2023).","journal-title":"J. Clin. Med."},{"key":"918_CR39","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.cmet.2023.10.018","volume":"35","author":"C Pan","year":"2023","unstructured":"Pan, C. et al. Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. Cell Metab. 35, 2231\u20132249.e7 (2023).","journal-title":"Cell Metab."},{"key":"918_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000627","volume":"9","author":"D Rayapati","year":"2025","unstructured":"Rayapati, D., McGlynn, K. A., Groopman, J. D. & Kim, A. K. Environmental exposures and the risk of hepatocellular carcinoma. Hepatology Commun. 9, e0627 (2025).","journal-title":"Hepatology Commun."},{"key":"918_CR41","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","volume":"610","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature 610, 562\u2013568 (2022).","journal-title":"Nature"},{"key":"918_CR42","doi-asserted-by":"publisher","first-page":"154337","DOI":"10.1016\/j.metabol.2020.154337","volume":"111S","author":"A Mukherji","year":"2020","unstructured":"Mukherji, A., Dachraoui, M. & Baumert, T. F. Perturbation of the circadian clock and pathogenesis of NAFLD. Metabolism 111S, 154337 (2020).","journal-title":"Metabolism"},{"key":"918_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ccell.2016.10.007","volume":"30","author":"NM Kettner","year":"2016","unstructured":"Kettner, N. M. et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell 30, 909\u2013924 (2016).","journal-title":"Cancer Cell"},{"key":"918_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","volume":"70","author":"N Ganne-Carrie","year":"2019","unstructured":"Ganne-Carrie, N. & Nahon, P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J. Hepatol. 70, 284\u2013293 (2019).","journal-title":"J. Hepatol."},{"key":"918_CR45","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","volume":"20","author":"LA Diaz","year":"2023","unstructured":"Diaz, L. A., Arab, J. P., Louvet, A., Bataller, R. & Arrese, M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 20, 764\u2013783 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR46","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1053\/j.gastro.2020.12.011","volume":"160","author":"CA Emdin","year":"2021","unstructured":"Emdin, C. A. et al. Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. Gastroenterology 160, 1620\u20131633.e13 (2021).","journal-title":"Gastroenterology"},{"key":"918_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2021.10.005","volume":"76","author":"JB Whitfield","year":"2022","unstructured":"Whitfield, J. B. et al. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J. Hepatol. 76, 275\u2013282 (2022).","journal-title":"J. Hepatol."},{"key":"918_CR48","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ng.3417","volume":"47","author":"S Buch","year":"2015","unstructured":"Buch, S. et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat. Genet. 47, 1443\u20131448 (2015).","journal-title":"Nat. Genet."},{"key":"918_CR49","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461\u20131465 (2008).","journal-title":"Nat. Genet."},{"key":"918_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ng.488","volume":"42","author":"C Tian","year":"2010","unstructured":"Tian, C., Stokowski, R. P., Kershenobich, D., Ballinger, D. G. & Hinds, D. A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 42, 21\u201323 (2010).","journal-title":"Nat. Genet."},{"key":"918_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3350\/cmh.2020.0162","volume":"27","author":"YW Ting","year":"2021","unstructured":"Ting, Y. W. et al. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: results from a multi-ethnic Asian cohort. Clin. Mol. Hepatol. 27, 486\u2013498 (2021).","journal-title":"Clin. Mol. Hepatol."},{"key":"918_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000431","volume":"8","author":"TH Schwantes-An","year":"2024","unstructured":"Schwantes-An, T. H. et al. A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry. Hepatol. Commun. 8, e0431 (2024).","journal-title":"Hepatol. Commun."},{"key":"918_CR53","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","volume":"75","author":"R Pinyol","year":"2021","unstructured":"Pinyol, R. et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 75, 865\u2013878 (2021).","journal-title":"J. Hepatol."},{"key":"918_CR54","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","volume":"47","author":"K Schulze","year":"2015","unstructured":"Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505\u2013U106 (2015).","journal-title":"Nat. Genet."},{"key":"918_CR55","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1097\/HEP.0000000000000890","volume":"80","author":"Y Fu","year":"2024","unstructured":"Fu, Y., Maccioni, L., Wang, X. W., Greten, T. F. & Gao, B. Alcohol-associated liver cancer. Hepatology 80, 1462\u20131479 (2024).","journal-title":"Hepatology"},{"key":"918_CR56","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2019.07.028","volume":"157","author":"A Moeini","year":"2019","unstructured":"Moeini, A. et al. An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. Gastroenterology 157, 1383 (2019).","journal-title":"Gastroenterology"},{"key":"918_CR57","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.devcel.2022.06.003","volume":"57","author":"R Donne","year":"2022","unstructured":"Donne, R. et al. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD. Dev. Cell 57, 1728 (2022).","journal-title":"Dev. Cell"},{"key":"918_CR58","doi-asserted-by":"publisher","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","volume":"400","author":"S Iturbe-Rey","year":"2025","unstructured":"Iturbe-Rey, S. et al. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis 400, 119053 (2025).","journal-title":"Atherosclerosis"},{"key":"918_CR59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s43018-020-00168-3","volume":"2","author":"R Rudalska","year":"2021","unstructured":"Rudalska, R. et al. LXR\u03b1 activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat. Cancer 2, 201\u2013217 (2021).","journal-title":"Nat. Cancer"},{"key":"918_CR60","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/sj.onc.1208304","volume":"24","author":"JW Lee","year":"2005","unstructured":"Lee, J. W. et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24, 1477\u20131480 (2005).","journal-title":"Oncogene"},{"key":"918_CR61","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","volume":"125","author":"ZA Knight","year":"2006","unstructured":"Knight, Z. A. et al. A pharmacological map of the PI3-K family defines a role for p110\u03b1 in insulin signaling. Cell 125, 733\u2013747 (2006).","journal-title":"Cell"},{"key":"918_CR62","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nm.2893","volume":"18","author":"M Zeybel","year":"2012","unstructured":"Zeybel, M. et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat. Med. 18, 1369\u20131377 (2012).","journal-title":"Nat. Med."},{"key":"918_CR63","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"A Ally","year":"2017","unstructured":"Ally, A. et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327 (2017).","journal-title":"Cell"},{"key":"918_CR64","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jhep.2025.08.017","volume":"84","author":"XD Zhou","year":"2026","unstructured":"Zhou, X. D. et al. Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J. Hepatol. 84, 254\u2013265 (2026).","journal-title":"J. Hepatol."},{"key":"918_CR65","doi-asserted-by":"publisher","first-page":"156080","DOI":"10.1016\/j.metabol.2024.156080","volume":"162","author":"A Armandi","year":"2024","unstructured":"Armandi, A., Rosso, C., Caviglia, G. P. & Bugianesi, E. An updated overview on hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease: trends, pathophysiology and risk-based surveillance. Metabolism 162, 156080 (2024).","journal-title":"Metabolism"},{"key":"918_CR66","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/a-2289-2298","volume":"44","author":"T Kodama","year":"2024","unstructured":"Kodama, T. & Takehara, T. Molecular genealogy of metabolic-associated hepatocellular carcinoma. Semin. Liver Dis. 44, 147\u2013158 (2024).","journal-title":"Semin. Liver Dis."},{"key":"918_CR67","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/hep.510260310","volume":"26","author":"S Tanaka","year":"1997","unstructured":"Tanaka, S., Mohr, L., Schmidt, E. V., Sugimachi, K. & Wands, J. R. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 26, 598\u2013604 (1997).","journal-title":"Hepatology"},{"key":"918_CR68","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3748\/wjg.v18.i15.1781","volume":"18","author":"J Takino","year":"2012","unstructured":"Takino, J., Yamagishi, S. & Takeuchi, M. Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression. World J. Gastroenterol. 18, 1781\u20131788 (2012).","journal-title":"World J. Gastroenterol."},{"key":"918_CR69","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.3390\/ijms13055982","volume":"13","author":"AM Yaser","year":"2012","unstructured":"Yaser, A. M. et al. The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int. J. Mol. Sci. 13, 5982\u20135997 (2012).","journal-title":"Int. J. Mol. Sci."},{"key":"918_CR70","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","volume":"82","author":"CD Fuchs","year":"2025","unstructured":"Fuchs, C. D. et al. Bile acid metabolism and signalling in liver disease. J. Hepatol. 82, 134\u2013153 (2025).","journal-title":"J. Hepatol."},{"key":"918_CR71","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1053\/j.gastro.2022.08.033","volume":"163","author":"BS Yeoh","year":"2022","unstructured":"Yeoh, B. S. et al. Enterohepatic shunt-driven cholemia predisposes to liver cancer. Gastroenterology 163, 1658 (2022).","journal-title":"Gastroenterology"},{"key":"918_CR72","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jcmgh.2021.11.012","volume":"13","author":"S Gallage","year":"2022","unstructured":"Gallage, S. et al. Spontaneous cholemia in C57BL\/6 mice predisposes to liver cancer in NASH. Cell Mol. Gastroenterol. Hepatol. 13, 875\u2013878 (2022).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"918_CR73","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2018.09.004","volume":"175","author":"V Singh","year":"2018","unstructured":"Singh, V. et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell 175, 679\u2013694.e22 (2018).","journal-title":"Cell"},{"key":"918_CR74","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","volume":"79","author":"L Adorini","year":"2023","unstructured":"Adorini, L. & Trauner, M. FXR agonists in NASH treatment. J. Hepatol. 79, 1317\u20131331 (2023).","journal-title":"J. Hepatol."},{"key":"918_CR75","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","volume":"67","author":"F Yang","year":"2007","unstructured":"Yang, F. et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67, 863\u2013867 (2007).","journal-title":"Cancer Res."},{"key":"918_CR76","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/hep.32105","volume":"75","author":"S Fan","year":"2022","unstructured":"Fan, S. et al. YAP-TEAD mediates PPAR \u03b1-induced hepatomegaly and liver regeneration in mice. Hepatology 75, 74\u201388 (2022).","journal-title":"Hepatology"},{"key":"918_CR77","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2025-100186","volume":"3","author":"B Bueloni","year":"2025","unstructured":"Bueloni, B., Garcia Fernandez de Barrena, M., Avila, M. A., Bayo, J. & Mazzolini, G. Epigenetic mechanisms involved in hepatocellular carcinoma development and progression. eGastroenterology 3, e100186 (2025).","journal-title":"eGastroenterology"},{"key":"918_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13046-022-02297-2","volume":"41","author":"MR Braghini","year":"2022","unstructured":"Braghini, M. R. et al. Epigenetic remodelling in human hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 41, 107 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"918_CR79","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2017.05.015","volume":"67","author":"L Wei","year":"2017","unstructured":"Wei, L. et al. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J. Hepatol. 67, 758\u2013769 (2017).","journal-title":"J. Hepatol."},{"key":"918_CR80","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1053\/j.gastro.2020.05.056","volume":"159","author":"C Chai","year":"2020","unstructured":"Chai, C. et al. Agonist of RORA attenuates nonalcoholic fatty liver progression in mice via up-regulation of microRNA 122. Gastroenterology 159, 999 (2020).","journal-title":"Gastroenterology"},{"key":"918_CR81","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1136\/gutjnl-2020-321548","volume":"70","author":"L Hao","year":"2021","unstructured":"Hao, L. et al. ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis. Gut 70, 1933\u20131945 (2021).","journal-title":"Gut"},{"key":"918_CR82","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","volume":"70","author":"B Gao","year":"2019","unstructured":"Gao, B., Ahmad, M. F., Nagy, L. E. & Tsukamoto, H. Inflammatory pathways in alcoholic steatohepatitis. J. Hepatol. 70, 249\u2013259 (2019).","journal-title":"J. Hepatol."},{"key":"918_CR83","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/hep.28530","volume":"64","author":"P Mandrekar","year":"2016","unstructured":"Mandrekar, P., Bataller, R., Tsukamoto, H. & Gao, B. Alcoholic hepatitis: translational approaches to develop targeted therapies. Hepatology 64, 1343\u20131355 (2016).","journal-title":"Hepatology"},{"key":"918_CR84","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/liv.13419","volume":"37","author":"P Nahon","year":"2017","unstructured":"Nahon, P. & Nault, J. C. Constitutional and functional genetics of human alcohol-related hepatocellular carcinoma. Liver Int. 37, 1591\u20131601 (2017).","journal-title":"Liver Int."},{"key":"918_CR85","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.1158\/0008-5472.CAN-16-1559","volume":"76","author":"C Allain","year":"2016","unstructured":"Allain, C., Angenard, G., Clement, B. & Coulouarn, C. Integrative genomic analysis identifies the core transcriptional hallmarks of human hepatocellular carcinoma. Cancer Res. 76, 6374\u20136381 (2016).","journal-title":"Cancer Res."},{"key":"918_CR86","first-page":"5","volume":"30","author":"HJ Edenberg","year":"2007","unstructured":"Edenberg, H. J. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res. Health 30, 5\u201313 (2007).","journal-title":"Alcohol Res. Health"},{"key":"918_CR87","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/ijc.21583","volume":"118","author":"N Homann","year":"2006","unstructured":"Homann, N. et al. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int. J. Cancer 118, 1998\u20132002 (2006).","journal-title":"Int. J. Cancer"},{"key":"918_CR88","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jhep.2019.06.018","volume":"71","author":"W Seo","year":"2019","unstructured":"Seo, W. et al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles. J. Hepatol. 71, 1000\u20131011 (2019).","journal-title":"J. Hepatol."},{"key":"918_CR89","doi-asserted-by":"publisher","first-page":"100466","DOI":"10.1016\/j.jhepr.2022.100466","volume":"4","author":"NW Habash","year":"2022","unstructured":"Habash, N. W., Sehrawat, T. S., Shah, V. H. & Cao, S. Epigenetics of alcohol-related liver diseases. JHEP Rep. 4, 100466 (2022).","journal-title":"JHEP Rep."},{"key":"918_CR90","doi-asserted-by":"publisher","first-page":"G857","DOI":"10.1152\/ajpgi.00044.2006","volume":"291","author":"SM Bailey","year":"2006","unstructured":"Bailey, S. M. et al. S-adenosylmethionine prevents chronic alcohol-induced mitochondrial dysfunction in the rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G857\u2013G867 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"918_CR91","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1152\/physrev.00047.2011","volume":"92","author":"SC Lu","year":"2012","unstructured":"Lu, S. C. & Mato, J. M. S. S-adenosylmethionine in liver health, injury, and cancer. Physiol. Rev. 92, 1515\u20131542 (2012).","journal-title":"Physiol. Rev."},{"key":"918_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-317","volume":"10","author":"A Csepregi","year":"2010","unstructured":"Csepregi, A. et al. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer 10, 317 (2010).","journal-title":"BMC Cancer"},{"key":"918_CR93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1055\/s-0034-1397347","volume":"35","author":"G Szabo","year":"2015","unstructured":"Szabo, G. & Satishchandran, A. MicroRNAs in alcoholic liver disease. Semin. Liver Dis. 35, 36\u201342 (2015).","journal-title":"Semin. Liver Dis."},{"key":"918_CR94","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.22569","volume":"48","author":"O Cheung","year":"2008","unstructured":"Cheung, O. et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 48, 1810\u20131820 (2008).","journal-title":"Hepatology"},{"key":"918_CR95","doi-asserted-by":"publisher","first-page":"ARTN e168476","DOI":"10.1172\/jci.insight.168476","volume":"9","author":"P Fern\u00e1ndez-Tussy","year":"2024","unstructured":"Fern\u00e1ndez-Tussy, P. et al. miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression. JCI Insight 9, ARTN e168476 (2024).","journal-title":"JCI Insight"},{"key":"918_CR96","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","volume":"30","author":"AL Gomes","year":"2016","unstructured":"Gomes, A. L. et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30, 161\u2013175 (2016).","journal-title":"Cancer Cell"},{"key":"918_CR97","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jhep.2019.12.016","volume":"72","author":"HY Ma","year":"2020","unstructured":"Ma, H. Y. et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J. Hepatol. 72, 946\u2013959 (2020).","journal-title":"J. Hepatol."},{"key":"918_CR98","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1126\/science.1140485","volume":"317","author":"WE Naugler","year":"2007","unstructured":"Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121\u2013124 (2007).","journal-title":"Science"},{"key":"918_CR99","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ccr.2009.08.021","volume":"16","author":"J Haybaeck","year":"2009","unstructured":"Haybaeck, J. et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16, 295\u2013308 (2009).","journal-title":"Cancer Cell"},{"key":"918_CR100","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","volume":"140","author":"EJ Park","year":"2010","unstructured":"Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197\u2013208 (2010).","journal-title":"Cell"},{"key":"918_CR101","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi, K. & Karin, M. NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309\u2013324 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"918_CR102","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2018.05.003","volume":"33","author":"D Dhar","year":"2018","unstructured":"Dhar, D. et al. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell 33, 1061\u20131077.e6 (2018).","journal-title":"Cancer Cell"},{"key":"918_CR103","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/cr.2010.183","volume":"21","author":"G He","year":"2011","unstructured":"He, G. & Karin, M. NF-\u03baB and STAT3 \u2014 key players in liver inflammation and cancer. Cell Res. 21, 159\u2013168 (2011).","journal-title":"Cell Res."},{"key":"918_CR104","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ejca.2006.01.011","volume":"42","author":"E Pikarsky","year":"2006","unstructured":"Pikarsky, E. & Ben-Neriah, Y. NF-\u03baB inhibition: a double-edged sword in cancer? Eur. J. Cancer 42, 779\u2013784 (2006).","journal-title":"Eur. J. Cancer"},{"key":"918_CR105","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2005.04.014","volume":"121","author":"S Maeda","year":"2005","unstructured":"Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKK\u03b2 couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977\u2013990 (2005).","journal-title":"Cell"},{"key":"918_CR106","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","volume":"26","author":"MJ Wolf","year":"2014","unstructured":"Wolf, M. J. et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26, 549\u2013564 (2014).","journal-title":"Cancer Cell"},{"key":"918_CR107","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccr.2006.12.016","volume":"11","author":"T Luedde","year":"2007","unstructured":"Luedde, T. et al. Deletion of NEMO\/IKK\u03b3 in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11, 119\u2013132 (2007).","journal-title":"Cancer Cell"},{"key":"918_CR108","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ccr.2010.03.021","volume":"17","author":"K Bettermann","year":"2010","unstructured":"Bettermann, K. et al. TAK1 suppresses a NEMO-dependent but NF-\u03baB-independent pathway to liver cancer. Cancer Cell 17, 481\u2013496 (2010).","journal-title":"Cancer Cell"},{"key":"918_CR109","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-06991-9","volume":"626","author":"W Fan","year":"2024","unstructured":"Fan, W. et al. Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver. Nature 626, 635\u2013642 (2024).","journal-title":"Nature"},{"key":"918_CR110","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/jgh.14867","volume":"35","author":"M Tobari","year":"2020","unstructured":"Tobari, M. et al. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J. Gastroenterol. Hepatol. 35, 862\u2013869 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"918_CR111","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","volume":"20","author":"LA Orci","year":"2022","unstructured":"Orci, L. A. et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin. Gastroenterol. Hepatol. 20, 283\u2013292 e210 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"918_CR112","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","volume":"36","author":"P Horn","year":"2024","unstructured":"Horn, P. & Tacke, F. Metabolic reprogramming in liver fibrosis. Cell Metab. 36, 1439\u20131455 (2024).","journal-title":"Cell Metab."},{"key":"918_CR113","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke, F., Puengel, T., Loomba, R. & Friedman, S. L. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J. Hepatol. 79, 552\u2013566 (2023).","journal-title":"J. Hepatol."},{"key":"918_CR114","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","volume":"178","author":"DA Jaitin","year":"2019","unstructured":"Jaitin, D. A. et al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell 178, 686\u2013698.e14 (2019).","journal-title":"Cell"},{"key":"918_CR115","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.cmet.2022.07.010","volume":"34","author":"P Zhang","year":"2022","unstructured":"Zhang, P. et al. Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment. Cell Metab. 34, 1359\u20131376.e7 (2022).","journal-title":"Cell Metab."},{"key":"918_CR116","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","volume":"75","author":"X Xiong","year":"2019","unstructured":"Xiong, X. et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol. Cell 75, 644\u2013660.e5 (2019).","journal-title":"Mol. Cell"},{"key":"918_CR117","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","volume":"52","author":"JS Seidman","year":"2020","unstructured":"Seidman, J. S. et al. Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis. Immunity 52, 1057\u20131074.e7 (2020).","journal-title":"Immunity"},{"key":"918_CR118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405746121","volume":"121","author":"S Ganguly","year":"2024","unstructured":"Ganguly, S. et al. Lipid-associated macrophages\u2019 promotion of fibrosis resolution during MASH regression requires TREM2. Proc. Natl Acad. Sci. USA 121, e2405746121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"918_CR119","doi-asserted-by":"publisher","first-page":"115310","DOI":"10.1016\/j.celrep.2025.115310","volume":"44","author":"L Zhou","year":"2025","unstructured":"Zhou, L. et al. Lipid droplet efferocytosis attenuates proinflammatory signaling in macrophages via TREM2- and MS4A7-dependent mechanisms. Cell Rep. 44, 115310 (2025).","journal-title":"Cell Rep."},{"key":"918_CR120","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1097\/HEP.0000000000001098","volume":"81","author":"G Fredrickson","year":"2025","unstructured":"Fredrickson, G. et al. TREM2 macrophages mediate the beneficial effects of bariatric surgery against MASH. Hepatology 81, 1776\u20131791 (2025).","journal-title":"Hepatology"},{"key":"918_CR121","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","volume":"575","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran, P. et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512 (2019).","journal-title":"Nature"},{"key":"918_CR122","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.immuni.2022.08.002","volume":"55","author":"M Guilliams","year":"2022","unstructured":"Guilliams, M. & Scott, C. L. Liver macrophages in health and disease. Immunity 55, 1515\u20131529 (2022).","journal-title":"Immunity"},{"key":"918_CR123","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166954","volume":"133","author":"DC Feng","year":"2023","unstructured":"Feng, D. C. et al. Monocyte-derived macrophages orchestrate multiple cell-type interactions to repair necrotic liver lesions in disease models. J. Clin. Invest. 133, e166954 (2023).","journal-title":"J. Clin. Invest."},{"key":"918_CR124","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","volume":"18","author":"YK Wen","year":"2021","unstructured":"Wen, Y. K., Lambrecht, J., Ju, C. & Tacke, F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol. Immunol. 18, 45\u201356 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"918_CR125","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","volume":"5","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy. Nat. Cancer 5, 167\u2013186 (2024).","journal-title":"Nat. Cancer"},{"key":"918_CR126","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","volume":"183","author":"A Sharma","year":"2020","unstructured":"Sharma, A. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 183, 377\u2013394.e21 (2020).","journal-title":"Cell"},{"key":"918_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43381-1","volume":"14","author":"S Cappuyns","year":"2023","unstructured":"Cappuyns, S. et al. PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nat. Commun. 14, 7825 (2023).","journal-title":"Nat. Commun."},{"key":"918_CR128","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","volume":"79","author":"J Tan","year":"2023","unstructured":"Tan, J. et al. TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J. Hepatol. 79, 126\u2013140 (2023).","journal-title":"J. Hepatol."},{"key":"918_CR129","doi-asserted-by":"publisher","first-page":"101505","DOI":"10.1016\/j.xcrm.2024.101505","volume":"5","author":"J Ning","year":"2024","unstructured":"Ning, J. et al. Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. Cell Rep. Med. 5, 101505 (2024).","journal-title":"Cell Rep. Med."},{"key":"918_CR130","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","volume":"27","author":"A Deczkowska","year":"2021","unstructured":"Deczkowska, A. et al. XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis. Nat. Med. 27, 1043\u20131054 (2021).","journal-title":"Nat. Med."},{"key":"918_CR131","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jhep.2017.01.008","volume":"66","author":"EC Heier","year":"2017","unstructured":"Heier, E. C. et al. Murine CD103+ dendritic cells protect against steatosis progression towards steatohepatitis. J. Hepatol. 66, 1241\u20131250 (2017).","journal-title":"J. Hepatol."},{"key":"918_CR132","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","volume":"179","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 179, 829\u2013845.e20 (2019).","journal-title":"Cell"},{"key":"918_CR133","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880\u2013886 (2010).","journal-title":"Nat. Med."},{"key":"918_CR134","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer 20, 485\u2013503 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"918_CR135","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue, R. et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612, 141\u2013147 (2022).","journal-title":"Nature"},{"key":"918_CR136","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jhep.2021.07.032","volume":"75","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. J. Hepatol. 75, 1271\u20131283 (2021).","journal-title":"J. Hepatol."},{"key":"918_CR137","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-024-01933-x","volume":"9","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Neutrophil extracellular traps in homeostasis and disease. Signal. Transduct. Target. Ther. 9, 235 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"918_CR138","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/HEP.0000000000000762","volume":"81","author":"Y Xia","year":"2025","unstructured":"Xia, Y. et al. Erratum: Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC. Hepatology 81, 947\u2013961 (2025).","journal-title":"Hepatology"},{"key":"918_CR139","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie, J. et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 71, 2093\u20132106 (2022).","journal-title":"Gut"},{"key":"918_CR140","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","volume":"25","author":"M Malehmir","year":"2019","unstructured":"Malehmir, M. et al. Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat. Med. 25, 641\u2013655 (2019).","journal-title":"Nat. Med."},{"key":"918_CR141","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jhepr.2019.10.001","volume":"1","author":"P Ramadori","year":"2019","unstructured":"Ramadori, P., Klag, T., Malek, N. P. & Heikenwalder, M. Platelets in chronic liver disease, from bench to bedside. JHEP Rep. 1, 448\u2013459 (2019).","journal-title":"JHEP Rep."},{"key":"918_CR142","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ccell.2022.08.004","volume":"40","author":"C Ma","year":"2022","unstructured":"Ma, C. et al. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell 40, 986\u2013998.e5 (2022).","journal-title":"Cancer Cell"},{"key":"918_CR143","doi-asserted-by":"crossref","first-page":"769a","DOI":"10.1002\/hep.25670","volume":"56","author":"P Chu","year":"2012","unstructured":"Chu, P. et al. Recruited CCR9+ macrophages promote murine liver fibrosis through induction of TGF-\u03b2 in hepatic stellate cells. Hepatology 56, 769a (2012).","journal-title":"Hepatology"},{"key":"918_CR144","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jhep.2007.01.029","volume":"46","author":"E Borkham-Kamphorst","year":"2007","unstructured":"Borkham-Kamphorst, E. et al. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J. Hepatol. 46, 1064\u20131074 (2007).","journal-title":"J. Hepatol."},{"key":"918_CR145","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","volume":"382","author":"TG Simon","year":"2020","unstructured":"Simon, T. G. et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N. Engl. J. Med. 382, 1018\u20131028 (2020).","journal-title":"N. Engl. J. Med."},{"key":"918_CR146","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","volume":"592","author":"M Dudek","year":"2021","unstructured":"Dudek, M. et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature 592, 444\u2013449 (2021).","journal-title":"Nature"},{"key":"918_CR147","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature16969","volume":"531","author":"C Ma","year":"2016","unstructured":"Ma, C. et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531, 253\u2013257 (2016).","journal-title":"Nature"},{"key":"918_CR148","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1056\/NEJMcibr2106594","volume":"385","author":"RK Kelley","year":"2021","unstructured":"Kelley, R. K. & Greten, T. F. Hepatocellular carcinoma \u2014 origins and outcomes. N. Engl. J. Med. 385, 280\u2013282 (2021).","journal-title":"N. Engl. J. Med."},{"key":"918_CR149","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151\u2013172 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"918_CR150","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","volume":"160","author":"B Heinrich","year":"2021","unstructured":"Heinrich, B. et al. Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice. Gastroenterology 160, 331\u2013345.e336 (2021).","journal-title":"Gastroenterology"},{"key":"918_CR151","doi-asserted-by":"publisher","first-page":"101065","DOI":"10.1016\/j.jhepr.2024.101065","volume":"6","author":"N Ben Khaled","year":"2024","unstructured":"Ben Khaled, N. et al. Atezolizumab\/bevacizumab or lenvatinib in hepatocellular carcinoma: multicenter real-world study with focus on bleeding and thromboembolic events. JHEP Rep. 6, 101065 (2024).","journal-title":"JHEP Rep."},{"key":"918_CR152","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/HEP.0000000000001328","volume":"83","author":"JC Ahn","year":"2026","unstructured":"Ahn, J. C. et al. Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: a real-world analysis using target trial emulation. Hepatology 83, 249\u2013260 (2026).","journal-title":"Hepatology"},{"key":"918_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823 (2013).","journal-title":"Nat. Commun."},{"key":"918_CR154","doi-asserted-by":"publisher","first-page":"101421","DOI":"10.1016\/j.jhepr.2025.101421","volume":"7","author":"RF Schwabe","year":"2025","unstructured":"Schwabe, R. F., Tacke, F., Sugimoto, A. & Friedman, S. L. Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 7, 101421 (2025).","journal-title":"JHEP Rep."},{"key":"918_CR155","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41575-025-01068-6","volume":"22","author":"RF Schwabe","year":"2025","unstructured":"Schwabe, R. F. & Brenner, D. A. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease. Nat. Rev. Gastroenterol. Hepatol. 22, 481\u2013499 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR156","doi-asserted-by":"publisher","first-page":"1132085","DOI":"10.3389\/fendo.2023.1132085","volume":"14","author":"PP Zhang","year":"2023","unstructured":"Zhang, P. P. et al. Single-cell RNA transcriptomics reveals differences in the immune status of alcoholic and hepatitis B virus-related liver cirrhosis. Front. Endocrinol. 14, 1132085 (2023).","journal-title":"Front. Endocrinol."},{"key":"918_CR157","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41423-025-01343-1","volume":"22","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Infiltrating macrophages replace Kupffer cells and play diverse roles in severe alcohol-associated hepatitis. Cell Mol. Immunol. 22, 1262\u20131275 (2025).","journal-title":"Cell Mol. Immunol."},{"key":"918_CR158","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/acer.70019","volume":"49","author":"MAS Khan","year":"2025","unstructured":"Khan, M. A. S. et al. Neutrophil extracellular traps (NETs) and NETosis in alcohol-associated diseases: a systematic review. Alcohol Clin. Exp. Res. 49, 697\u2013711 (2025).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"918_CR159","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","volume":"158","author":"V Azzu","year":"2020","unstructured":"Azzu, V., Vacca, M., Virtue, S., Allison, M. & Vidal-Puig, A. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology 158, 1899\u20131912 (2020).","journal-title":"Gastroenterology"},{"key":"918_CR160","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.175629","volume":"9","author":"S Nielsen","year":"2024","unstructured":"Nielsen, S. & Jensen, M. D. Insulin regulation of regional lipolysis in upper-body obese and lean humans. JCI Insight 9, e175629 (2024).","journal-title":"JCI Insight"},{"key":"918_CR161","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","volume":"160","author":"RJ Perry","year":"2015","unstructured":"Perry, R. J. et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160, 745\u2013758 (2015).","journal-title":"Cell"},{"key":"918_CR162","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","volume":"76","author":"F Foerster","year":"2022","unstructured":"Foerster, F., Gairing, S. J., Muller, L. & Galle, P. R. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options. J. Hepatol. 76, 446\u2013457 (2022).","journal-title":"J. Hepatol."},{"key":"918_CR163","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jhep.2023.01.014","volume":"78","author":"A Falkevall","year":"2023","unstructured":"Falkevall, A. et al. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue. J. Hepatol. 78, 901\u2013913 (2023).","journal-title":"J. Hepatol."},{"key":"918_CR164","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2023.10.039","volume":"80","author":"M Boesch","year":"2024","unstructured":"Boesch, M. et al. Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH. J. Hepatol. 80, 397\u2013408 (2024).","journal-title":"J. Hepatol."},{"key":"918_CR165","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.29578","volume":"67","author":"AJ Montano-Loza","year":"2018","unstructured":"Montano-Loza, A. J. et al. Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology 67, 914\u2013923 (2018).","journal-title":"Hepatology"},{"key":"918_CR166","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gut.2008.164053","volume":"58","author":"T Ohki","year":"2009","unstructured":"Ohki, T. et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 58, 839\u2013844 (2009).","journal-title":"Gut"},{"key":"918_CR167","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.3390\/cancers13235980","volume":"13","author":"K Imai","year":"2021","unstructured":"Imai, K. et al. Higher accumulation of visceral adipose tissue is an independent risk factor for hepatocellular carcinoma among viral hepatitis patients with non-cirrhotic livers. Cancers 13, 5980 (2021).","journal-title":"Cancers"},{"key":"918_CR168","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144801","volume":"131","author":"B Liu","year":"2021","unstructured":"Liu, B. et al. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J. Clin. Invest. 131, e144801 (2021).","journal-title":"J. Clin. Invest."},{"key":"918_CR169","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3390\/cancers13102305","volume":"13","author":"GP Caviglia","year":"2021","unstructured":"Caviglia, G. P. et al. Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancers 13, 2305 (2021).","journal-title":"Cancers"},{"key":"918_CR170","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154940","volume":"8","author":"SK Gunasekar","year":"2023","unstructured":"Gunasekar, S. K. et al. Adipose-targeted SWELL1 deletion exacerbates obesity- and age-related nonalcoholic fatty liver disease. JCI Insight 8, e154940 (2023).","journal-title":"JCI Insight"},{"key":"918_CR171","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jcmgh.2022.10.002","volume":"15","author":"SH Park","year":"2023","unstructured":"Park, S. H. et al. Ethanol and its nonoxidative metabolites promote acute liver injury by inducing ER stress, adipocyte death, and lipolysis. Cell Mol. Gastroenterol. Hepatol. 15, 281\u2013306 (2023).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"918_CR172","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature07540","volume":"457","author":"PJ Turnbaugh","year":"2009","unstructured":"Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480\u2013484 (2009).","journal-title":"Nature"},{"key":"918_CR173","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","volume":"22","author":"HC Lau","year":"2025","unstructured":"Lau, H. C., Zhang, X. & Yu, J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 22, 619\u2013638 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR174","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809302","volume":"11","author":"AA Kolodziejczyk","year":"2019","unstructured":"Kolodziejczyk, A. A., Zheng, D., Shibolet, O. & Elinav, E. The role of the microbiome in NAFLD and NASH. EMBO Mol. Med. 11, e9302 (2019).","journal-title":"EMBO Mol. Med."},{"key":"918_CR175","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","volume":"70","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 70, 761\u2013774 (2021).","journal-title":"Gut"},{"key":"918_CR176","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012377","volume":"20","author":"S Zeng","year":"2024","unstructured":"Zeng, S. & Schnabl, B. Gut mycobiome alterations and implications for liver diseases. PLoS Pathog. 20, e1012377 (2024).","journal-title":"PLoS Pathog."},{"key":"918_CR177","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.chom.2016.10.016","volume":"20","author":"AJ Macpherson","year":"2016","unstructured":"Macpherson, A. J., Heikenwalder, M. & Ganal-Vonarburg, S. C. The liver at the nexus of host-microbial interactions. Cell Host Microbe 20, 561\u2013571 (2016).","journal-title":"Cell Host Microbe"},{"key":"918_CR178","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrgastro.2017.72","volume":"14","author":"LX Yu","year":"2017","unstructured":"Yu, L. X. & Schwabe, R. F. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat. Rev. Gastroenterol. Hepatol. 14, 527\u2013539 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR179","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","volume":"71","author":"J Mouries","year":"2019","unstructured":"Mouries, J. et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J. Hepatol. 71, 1216\u20131228 (2019).","journal-title":"J. Hepatol."},{"key":"918_CR180","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","volume":"21","author":"DH Dapito","year":"2012","unstructured":"Dapito, D. H. et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504\u2013516 (2012).","journal-title":"Cancer Cell"},{"key":"918_CR181","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/lipd.12408","volume":"25","author":"C Kim","year":"2024","unstructured":"Kim, C., Tsai, T. H., Lopez, R., McCullough, A. & Kasumov, T. Obeticholic acid\u2019s effect on HDL function in MASH varies by diabetic status. Lipids 25, 221\u2013231 (2024).","journal-title":"Lipids"},{"key":"918_CR182","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12347","volume":"499","author":"S Yoshimoto","year":"2013","unstructured":"Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97\u2013101 (2013).","journal-title":"Nature"},{"key":"918_CR183","doi-asserted-by":"publisher","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, eaan5931 (2018).","journal-title":"Science"},{"key":"918_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35861-1","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang, M. et al. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat. Commun. 14, 228 (2023).","journal-title":"Nat. Commun."},{"key":"918_CR185","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","volume":"79","author":"Q Song","year":"2023","unstructured":"Song, Q. et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J. Hepatol. 79, 1352\u20131365 (2023).","journal-title":"J. Hepatol."},{"key":"918_CR186","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","volume":"18","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Gut microbiome, liver immunology, and liver diseases. Cell Mol. Immunol. 18, 4\u201317 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"918_CR187","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41564-024-01890-9","volume":"10","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice. Nat. Microbiol. 10, 169\u2013184 (2025).","journal-title":"Nat. Microbiol."},{"key":"918_CR188","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100013","volume":"1","author":"L Maccioni","year":"2023","unstructured":"Maccioni, L. et al. Alcohol-associated bowel disease: new insights into pathogenesis. eGastroenterology 1, e10001 (2023).","journal-title":"eGastroenterology"},{"key":"918_CR189","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J. Hepatol. 72, 558\u2013577 (2020).","journal-title":"J. Hepatol."},{"key":"918_CR190","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176345","volume":"134","author":"B Mackowiak","year":"2024","unstructured":"Mackowiak, B., Fu, Y., Maccioni, L. & Gao, B. Alcohol-associated liver disease. J. Clin. Invest. 134, e176345 (2024).","journal-title":"J. Clin. Invest."},{"key":"918_CR191","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","volume":"10","author":"A Wree","year":"2013","unstructured":"Wree, A., Broderick, L., Canbay, A., Hoffman, H. M. & Feldstein, A. E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627\u2013636 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR192","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jhep.2007.04.019","volume":"47","author":"CA Rivera","year":"2007","unstructured":"Rivera, C. A. et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47, 571\u2013579 (2007).","journal-title":"J. Hepatol."},{"key":"918_CR193","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3350\/cmh.2022.0039","volume":"28","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4. Clin. Mol. Hepatol. 28, 522\u2013539 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"918_CR194","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","volume":"30","author":"J Yuan","year":"2019","unstructured":"Yuan, J. et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 30, 675\u2013688 e677 (2019).","journal-title":"Cell Metab."},{"key":"918_CR195","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","volume":"28","author":"AS Meijnikman","year":"2022","unstructured":"Meijnikman, A. S. et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat. Med. 28, 2100\u20132106 (2022).","journal-title":"Nat. Med."},{"key":"918_CR196","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/jgh.16869","volume":"40","author":"R Stamation","year":"2025","unstructured":"Stamation, R. Endogenous ethanol production in the human alimentary tract: a literature review. J. Gastroenterol. Hepatol. 40, 783\u2013790 (2025).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"918_CR197","doi-asserted-by":"publisher","first-page":"1577724","DOI":"10.3389\/fmicb.2025.1577724","volume":"16","author":"M Buchynskyi","year":"2025","unstructured":"Buchynskyi, M. et al. Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease. Front. Microbiol. 16, 1577724 (2025).","journal-title":"Front. Microbiol."},{"key":"918_CR198","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41564-025-02225-y","volume":"11","author":"CL Hsu","year":"2026","unstructured":"Hsu, C. L. et al. Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohort. Nat. Microbiol. 11, 415\u2013428 (2026).","journal-title":"Nat. Microbiol."},{"key":"918_CR199","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41423-025-01326-2","volume":"22","author":"M Xie","year":"2025","unstructured":"Xie, M., Li, X., Lau, H. C. & Yu, J. The gut microbiota in cancer immunity and immunotherapy. Cell Mol. Immunol. 22, 1012\u20131031 (2025).","journal-title":"Cell Mol. Immunol."},{"key":"918_CR200","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41420-025-02413-z","volume":"11","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota. Cell Death Discov. 11, 140 (2025).","journal-title":"Cell Death Discov."},{"key":"918_CR201","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1172\/JCI124376","volume":"129","author":"H Shen","year":"2019","unstructured":"Shen, H., Jiang, L., Lin, J. D., Omary, M. B. & Rui, L. Brown fat activation mitigates alcohol-induced liver steatosis and injury in mice. J. Clin. Invest. 129, 2305\u20132317 (2019).","journal-title":"J. Clin. Invest."},{"key":"918_CR202","doi-asserted-by":"publisher","first-page":"101813","DOI":"10.1016\/j.molmet.2023.101813","volume":"78","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Sympathetic overdrive and unrestrained adipose lipolysis drive alcohol-induced hepatic steatosis in rodents. Mol. Metab. 78, 101813 (2023).","journal-title":"Mol. Metab."},{"key":"918_CR203","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cmet.2024.04.020","volume":"36","author":"W Xie","year":"2024","unstructured":"Xie, W. et al. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti. Cell Metab. 36, 1269\u20131286.e9 (2024).","journal-title":"Cell Metab."},{"key":"918_CR204","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"918_CR205","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450\u20131462 (2019).","journal-title":"N. Engl. J. Med."},{"key":"918_CR206","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","volume":"24","author":"A Do","year":"2025","unstructured":"Do, A., Zahrawi, F. & Mehal, W. Z. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat. Rev. Drug Discov. 24, 171\u2013189 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"918_CR207","doi-asserted-by":"publisher","first-page":"S721","DOI":"10.1016\/S0168-8278(22)01761-5","volume":"77","author":"M Cooreman","year":"2022","unstructured":"Cooreman, M. et al. The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change. J. Hepatol. 77, S721\u2013S722 (2022).","journal-title":"J. Hepatol."},{"key":"918_CR208","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/metabo11020073","volume":"11","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A. et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 11, 73 (2021).","journal-title":"Metabolites"},{"key":"918_CR209","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/ijms23063107","volume":"23","author":"T Androutsakos","year":"2022","unstructured":"Androutsakos, T. et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int. J. Mol. Sci. 23, 3107 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"918_CR210","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1038\/s41591-024-02958-z","volume":"30","author":"JV Lazarus","year":"2024","unstructured":"Lazarus, J. V. et al. Opportunities and challenges following approval of resmetirom for MASH liver disease. Nat. Med. 30, 3402\u20133405 (2024).","journal-title":"Nat. Med."},{"key":"918_CR211","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cmet.2024.04.015","volume":"36","author":"S Gallage","year":"2024","unstructured":"Gallage, S. et al. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR\u03b1 and PCK1. Cell Metab. 36, 1371\u20131393.e7 (2024).","journal-title":"Cell Metab."},{"key":"918_CR212","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","volume":"77","author":"AG Singal","year":"2022","unstructured":"Singal, A. G. et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J. Hepatol. 77, 128\u2013139 (2022).","journal-title":"J. Hepatol."},{"key":"918_CR213","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cgh.2018.10.031","volume":"17","author":"DT Choi","year":"2019","unstructured":"Choi, D. T. et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. Clin. Gastroenterol. Hepatol. 17, 976\u2013987.e4 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"918_CR214","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal, A. G., Kanwal, F. & Llovet, J. M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat. Rev. Clin. Oncol. 20, 864\u2013884 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"918_CR215","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.31309","volume":"73","author":"E Wolf","year":"2021","unstructured":"Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D. & Singal, A. G. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology 73, 713\u2013725 (2021).","journal-title":"Hepatology"},{"key":"918_CR216","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jhep.2021.01.041","volume":"75","author":"P Gupta","year":"2021","unstructured":"Gupta, P. et al. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J. Hepatol. 75, 108\u2013119 (2021).","journal-title":"J. Hepatol."},{"key":"918_CR217","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2024.03.048","volume":"81","author":"DH Kim","year":"2024","unstructured":"Kim, D. H. et al. Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC. J. Hepatol. 81, 461\u2013470 (2024).","journal-title":"J. Hepatol."},{"key":"918_CR218","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"918_CR219","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver.","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J. Hepatol. 69, 182\u2013236 (2018).","journal-title":"J. Hepatol."},{"key":"918_CR220","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata, M. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int. 11, 317\u2013370 (2017).","journal-title":"Hepatol. Int."},{"key":"918_CR221","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","volume":"14","author":"S Berhane","year":"2016","unstructured":"Berhane, S. et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin. Gastroenterol. Hepatol. 14, 875 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"918_CR222","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/hep.32185","volume":"75","author":"AG Singal","year":"2022","unstructured":"Singal, A. G. et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology 75, 541\u2013549 (2022).","journal-title":"Hepatology"},{"key":"918_CR223","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cgh.2021.04.018","volume":"20","author":"AG Singal","year":"2022","unstructured":"Singal, A. G. et al. Doylestown plus and GALAD demonstrate high sensitivity for HCC detection in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 20, 953 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"918_CR224","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","volume":"18","author":"J Best","year":"2020","unstructured":"Best, J. et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 18, 728 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"918_CR225","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cgh.2022.01.047","volume":"21","author":"N Tayob","year":"2023","unstructured":"Tayob, N., Kanwal, F., Alsarraj, A., Hernaez, R. & El-Serag, H. B. The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States. Clin. Gastroenterol. Hepatol. 21, 415\u2013423.e4 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"918_CR226","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/j.gastro.2009.10.031","volume":"138","author":"AS Lok","year":"2010","unstructured":"Lok, A. S. et al. Des-\u03b3-carboxy prothrombin and \u03b1-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138, 493\u2013502 (2010).","journal-title":"Gastroenterology"},{"key":"918_CR227","doi-asserted-by":"publisher","first-page":"104962","DOI":"10.1016\/j.ebiom.2023.104962","volume":"100","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. Cell-free DNA testing for early hepatocellular carcinoma surveillance. eBioMedicine 100, 104962 (2024).","journal-title":"eBioMedicine"},{"key":"918_CR228","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.cgh.2021.08.010","volume":"20","author":"NP Chalasani","year":"2022","unstructured":"Chalasani, N. P. et al. Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 20, 173 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"918_CR229","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/hep4.1918","volume":"6","author":"N Lin","year":"2022","unstructured":"Lin, N. et al. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol. Commun. 6, 1753\u20131763 (2022).","journal-title":"Hepatol. Commun."},{"key":"918_CR230","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/S0168-8278(18)30444-6","volume":"68","author":"A Oussalah","year":"2018","unstructured":"Oussalah, A. et al. Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. J. Hepatol. 68, S113\u2013S114 (2018).","journal-title":"J. Hepatol."},{"key":"918_CR231","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1053\/j.gastro.2021.01.233","volume":"160","author":"AG Singal","year":"2021","unstructured":"Singal, A. G. et al. International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology 160, 2572\u20132584 (2021).","journal-title":"Gastroenterology"},{"key":"918_CR232","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18311-0","volume":"11","author":"N Sun","year":"2020","unstructured":"Sun, N. et al. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat. Commun. 11, 4489 (2020).","journal-title":"Nat. Commun."},{"key":"918_CR233","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1136\/gutjnl-2021-325036","volume":"71","author":"J von Felden","year":"2022","unstructured":"von Felden, J. et al. Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut 71, 2069\u20132080 (2022).","journal-title":"Gut"},{"key":"918_CR234","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41575-024-00919-y","volume":"21","author":"J Calderaro","year":"2024","unstructured":"Calderaro, J., Zigutyt\u00e9, L., Truhn, D., Jaffe, A. & Kather, J. N. Artificial intelligence in liver cancer \u2014 new tools for research and patient management. Nat. Rev. Gastroenterol. Hepatol. 21, 585\u2013599 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR235","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jhep.2022.01.014","volume":"76","author":"J Calderaro","year":"2022","unstructured":"Calderaro, J., Seraphin, T. P., Luedde, T. & Simon, T. G. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J. Hepatol. 76, 1348\u20131361 (2022).","journal-title":"J. Hepatol."},{"key":"918_CR236","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S. & Llovet, J. M. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol. 10, 395\u2013404 (2024).","journal-title":"JAMA Oncol."},{"key":"918_CR237","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","volume":"3","author":"JM Llovet","year":"2022","unstructured":"Llovet, J. M. et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat. Cancer 3, 386\u2013401 (2022).","journal-title":"Nat. Cancer"},{"key":"918_CR238","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet, J. M. et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 21, 294\u2013311 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"918_CR239","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 293\u2013313 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR240","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345\u20131362 (2022).","journal-title":"Lancet"},{"key":"918_CR241","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2024.42.3_suppl.482","volume":"42","author":"M Kudo","year":"2024","unstructured":"Kudo, M. et al. Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study. J. Clin. Oncol. 42, 482\u2013482 (2024).","journal-title":"J. Clin. Oncol."},{"key":"918_CR242","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00270-019-02363-x","volume":"43","author":"S Young","year":"2020","unstructured":"Young, S. et al. Transarterial chemoembolization of hepatocellular carcinoma: propensity score matching study comparing survival and complications in patients with nonalcoholic steatohepatitis versus other causes cirrhosis. Cardiovasc. Inter. Rad. 43, 65\u201375 (2020).","journal-title":"Cardiovasc. Inter. Rad."},{"key":"918_CR243","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000501484","volume":"8","author":"C Schotten","year":"2019","unstructured":"Schotten, C. et al. NAFLD-associated comorbidities in advanced stage HCC do not alter the safety and efficacy of Yttrium-90 radioembolization. Liver Cancer 8, 491\u2013504 (2019).","journal-title":"Liver Cancer"},{"key":"918_CR244","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"918_CR245","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).","journal-title":"NEJM Evid."},{"key":"918_CR246","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"918_CR247","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"918_CR248","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"918_CR249","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/JCO.2023.41.4_suppl.578","volume":"41","author":"ZG Ren","year":"2023","unstructured":"Ren, Z. G. et al. Tebotelimab, a PD-1\/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and\/or immunotherapy: An open-label, single-arm, phase 1\/2 dose-escalation and expansion study. J. Clin. Oncol. 41, 578\u2013578 (2023).","journal-title":"J. Clin. Oncol."},{"key":"918_CR250","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4115","volume":"40","author":"BC Xing","year":"2022","unstructured":"Xing, B. C., Da, X., Zhang, Y. Q. & Ma, Y. A phase II study combining KN046 (an anti-PD-L1\/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): updated efficacy and safety results. J. Clin. Oncol. 40, 4115 (2022).","journal-title":"J. Clin. Oncol."},{"key":"918_CR251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1238667","volume":"14","author":"Q Qiao","year":"2023","unstructured":"Qiao, Q. et al. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib\/II single-arm clinical trial. Front. Immunology 14, 1238667 (2023).","journal-title":"Front. Immunology"},{"key":"918_CR252","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e16154","volume":"41","author":"Q Qi","year":"2023","unstructured":"Qi, Q. A study of cadonilimab combined with regorafenib as second-line or later therapy in patients with advanced hepatocellular carcinoma (aHCC). J. Clin. Oncol. 41, e16154 (2023).","journal-title":"J. Clin. Oncol."},{"key":"918_CR253","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1200\/JCO.2024.42.3_suppl.478","volume":"42","author":"G Liang","year":"2024","unstructured":"Liang, G. et al. The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: a phase II clinical trial. J. Clin. Oncol. 42, 478\u2013478 (2024).","journal-title":"J. Clin. Oncol."},{"key":"918_CR254","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","volume":"161","author":"PK Haber","year":"2021","unstructured":"Haber, P. K. et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). Gastroenterology 161, 879\u2013898 (2021).","journal-title":"Gastroenterology"},{"key":"918_CR255","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s44276-024-00038-w","volume":"2","author":"YL Wu","year":"2024","unstructured":"Wu, Y. L. et al. Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors. BJC Rep. 2, 8 (2024).","journal-title":"BJC Rep."},{"key":"918_CR256","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","volume":"79","author":"T Meyer","year":"2023","unstructured":"Meyer, T., Galani, S., Lopes, A. & Vogel, A. Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease. J. Hepatol. 79, e73\u2013e76 (2023).","journal-title":"J. Hepatol."},{"key":"918_CR257","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","volume":"9","author":"W Zhu","year":"2024","unstructured":"Zhu, W. et al. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma. Signal. Transduct. Target. Ther. 9, 101 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"918_CR258","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","volume":"77","author":"S Wabitsch","year":"2022","unstructured":"Wabitsch, S. et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J. Hepatol. 77, 748\u2013760 (2022).","journal-title":"J. Hepatol."},{"key":"918_CR259","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"918_CR260","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"918_CR261","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"918_CR262","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"918_CR263","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"918_CR264","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi, M. et al. Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol. Cancer 17, 129 (2018).","journal-title":"Mol. Cancer"},{"key":"918_CR265","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/liv.14706","volume":"41","author":"CN Wong","year":"2021","unstructured":"Wong, C. N. et al. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int. 41, 192\u2013203 (2021).","journal-title":"Liver Int."},{"key":"918_CR266","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"918_CR267","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/imm.13677","volume":"170","author":"D Wu","year":"2023","unstructured":"Wu, D. & Li, Y. Application of adoptive cell therapy in hepatocellular carcinoma. Immunology 170, 453\u2013469 (2023).","journal-title":"Immunology"},{"key":"918_CR268","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler, M. E., Stuhler, G. & Bargou, R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat. Rev. Clin. Oncol. 21, 539\u2013560 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"918_CR269","doi-asserted-by":"publisher","first-page":"Tps624","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS624","volume":"41","author":"CQ Xie","year":"2023","unstructured":"Xie, C. Q. et al. A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC). J. Clin. Oncol. 41, Tps624 (2023).","journal-title":"J. Clin. Oncol."},{"key":"918_CR270","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.eclinm.2023.102175","volume":"63","author":"Q Fu","year":"2023","unstructured":"Fu, Q. et al. RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine 63, 102175 (2023).","journal-title":"EClinicalMedicine"},{"key":"918_CR271","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","volume":"29","author":"KX Du","year":"2021","unstructured":"Du, K. X. et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol. Ther. 29, 1572\u20131584 (2021).","journal-title":"Mol. Ther."},{"key":"918_CR272","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/s41401-024-01287-8","volume":"45","author":"RX Sun","year":"2024","unstructured":"Sun, R. X. et al. GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma. Acta Pharmacol. Sin. 45, 1937\u20131950 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"918_CR273","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","volume":"21","author":"EJ Sayour","year":"2024","unstructured":"Sayour, E. J., Boczkowski, D., Mitchell, D. A. & Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. Nat. Rev. Clin. Oncol. 21, 489\u2013500 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"918_CR274","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"918_CR275","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/2326-6066.CIR-21-0931","volume":"10","author":"S Peng","year":"2022","unstructured":"Peng, S. et al. Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma. Cancer Immunol. Res. 10, 728\u2013744 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"918_CR276","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"918_CR277","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000131","volume":"11","author":"S Sydor","year":"2020","unstructured":"Sydor, S. et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC. Clin. Transl. Gastroenterol. 11, e00131 (2020).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"918_CR278","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.30036","volume":"69","author":"FR Ponziani","year":"2019","unstructured":"Ponziani, F. R. et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69, 107\u2013120 (2019).","journal-title":"Hepatology"},{"key":"918_CR279","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jhep.2016.11.008","volume":"66","author":"G Ferrere","year":"2017","unstructured":"Ferrere, G. et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J. Hepatol. 66, 806\u2013815 (2017).","journal-title":"J. Hepatol."},{"key":"918_CR280","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/hepr.13473","volume":"50","author":"JP Arab","year":"2020","unstructured":"Arab, J. P., Arrese, M. & Shah, V. H. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: current concepts and perspectives. Hepatol. Res. 50, 407\u2013418 (2020).","journal-title":"Hepatol. Res."},{"key":"918_CR281","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","volume":"72","author":"RF Schwabe","year":"2020","unstructured":"Schwabe, R. F. & Greten, T. F. Gut microbiome in HCC \u2014 mechanisms, diagnosis and therapy. J. Hepatol. 72, 230\u2013238 (2020).","journal-title":"J. Hepatol."},{"key":"918_CR282","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","volume":"406","author":"SL Chan","year":"2025","unstructured":"Chan, S. L. et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet 406, 731\u2013778 (2025).","journal-title":"Lancet"},{"key":"918_CR283","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gutjnl-2022-327196","volume":"72","author":"S Buch","year":"2023","unstructured":"Buch, S. et al. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut 72, 381\u2013391 (2023).","journal-title":"Gut"},{"key":"918_CR284","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","volume":"4","author":"S Gallage","year":"2022","unstructured":"Gallage, S. et al. A researcher\u2019s guide to preclinical mouse NASH models. Nat. Metab. 4, 1632\u20131649 (2022).","journal-title":"Nat. Metab."},{"key":"918_CR285","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jhep.2020.04.011","volume":"73","author":"YA Nevzorova","year":"2020","unstructured":"Nevzorova, Y. A., Boyer-Diaz, Z., Cubero, F. J. & Gracia-Sancho, J. Animal models for liver disease \u2014 a practical approach for translational research. J. Hepatol. 73, 423\u2013440 (2020).","journal-title":"J. Hepatol."},{"key":"918_CR286","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jcmgh.2021.05.010","volume":"12","author":"S Ganguly","year":"2021","unstructured":"Ganguly, S. et al. Nonalcoholic steatohepatitis and HCC in a hyperphagic mouse accelerated by Western diet. Cell Mol. Gastroenterol. Hepatol. 12, 891\u2013920 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"918_CR287","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2014.07.001","volume":"26","author":"H Nakagawa","year":"2014","unstructured":"Nakagawa, H. et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26, 331\u2013343 (2014).","journal-title":"Cancer Cell"},{"key":"918_CR288","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1172\/JCI20513","volume":"113","author":"Y Horie","year":"2004","unstructured":"Horie, Y. et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113, 1774\u20131783 (2004).","journal-title":"J. Clin. Invest."},{"key":"918_CR289","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1749-6632.2010.05895.x","volume":"1216","author":"JC Crabbe","year":"2011","unstructured":"Crabbe, J. C., Harris, R. A. & Koob, G. F. Preclinical studies of alcohol binge drinking. Ann. N. Y. Acad. Sci. 1216, 24\u201340 (2011).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"918_CR290","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ajpath.2024.11.011","volume":"196","author":"P Cao","year":"2026","unstructured":"Cao, P., Chao, X., Ni, H. M. & Ding, W. X. An update on animal models of alcohol-associated liver disease. Am. J. Pathol. 196, 4\u201319 (2026).","journal-title":"Am. J. Pathol."},{"key":"918_CR291","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nprot.2013.032","volume":"8","author":"A Bertola","year":"2013","unstructured":"Bertola, A., Mathews, S., Ki, S. H., Wang, H. & Gao, B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat. Protoc. 8, 627\u2013637 (2013).","journal-title":"Nat. Protoc."},{"key":"918_CR292","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc2191","volume":"7","author":"HK Seitz","year":"2007","unstructured":"Seitz, H. K. & Stickel, F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat. Rev. Cancer 7, 599\u2013612 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"918_CR293","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","volume":"75","author":"NF Lange","year":"2021","unstructured":"Lange, N. F., Radu, P. & Dufour, J. F. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. J. Hepatol. 75, 1217\u20131227 (2021).","journal-title":"J. Hepatol."},{"key":"918_CR294","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M., Zelber-Sagi, S., Henry, L. & Gerber, L. H. Lifestyle interventions in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 20, 708\u2013722 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"918_CR295","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367\u2013378.e5 (2015).","journal-title":"Gastroenterology"},{"key":"918_CR296","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/chi.2017.0269","volume":"14","author":"F Sirico","year":"2018","unstructured":"Sirico, F. et al. Effects of physical exercise on adiponectin, leptin, and inflammatory markers in childhood obesity: systematic review and meta-analysis. Child. Obes. 14, 207\u2013217 (2018).","journal-title":"Child. Obes."},{"key":"918_CR297","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1136\/gut.2006.112094","volume":"56","author":"SA Harrison","year":"2007","unstructured":"Harrison, S. A. & Day, C. P. Benefits of lifestyle modification in NAFLD. Gut 56, 1760\u20131769 (2007).","journal-title":"Gut"},{"key":"918_CR298","first-page":"527","volume":"71","author":"KK Clifton","year":"2021","unstructured":"Clifton, K. K., Ma, C. X., Fontana, L. & Peterson, L. L. Intermittent fasting in the prevention and treatment of cancer. CA Cancer J. Clin. 71, 527\u2013546 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"918_CR299","doi-asserted-by":"publisher","first-page":"948655","DOI":"10.3389\/fnut.2022.948655","volume":"9","author":"HK Varkaneh","year":"2022","unstructured":"Varkaneh, H. K. et al. Effects of the 5:2 intermittent fasting diet on non-alcoholic fatty liver disease: a randomized controlled trial. Front. Nutr. 9, 948655 (2022).","journal-title":"Front. Nutr."},{"key":"918_CR300","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-G\u00f3mez","year":"2017","unstructured":"Romero-G\u00f3mez, M., Zelber-Sagi, S. & Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 67, 829\u2013846 (2017).","journal-title":"J. Hepatol."},{"key":"918_CR301","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.bbi.2012.04.006","volume":"26","author":"N Kawanishi","year":"2012","unstructured":"Kawanishi, N. et al. Exercise training attenuates hepatic inflammation, fibrosis and macrophage infiltration during diet induced-obesity in mice. Brain Behav. Immun. 26, 931\u2013941 (2012).","journal-title":"Brain Behav. Immun."},{"key":"918_CR302","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/HEP.0000000000000645","volume":"82","author":"LA Diaz","year":"2025","unstructured":"Diaz, L. A. et al. New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease. Hepatology 82, 254\u2013271 (2025).","journal-title":"Hepatology"},{"key":"918_CR303","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0168-8278(01)00223-9","volume":"36","author":"CM Oneta","year":"2002","unstructured":"Oneta, C. M. et al. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J. Hepatol. 36, 47\u201352 (2002).","journal-title":"J. Hepatol."},{"key":"918_CR304","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","volume":"21","author":"BS Hofer","year":"2023","unstructured":"Hofer, B. S. et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis. Clin. Gastroenterol. Hepatol. 21, 2308\u20132317.e7 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00918-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:02:12Z","timestamp":1780315332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00918-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":304,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1038\/s41568-026-00918-y","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"24 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.L. received research support from Genentech and Roche, consultancy\/sponsored lecture fees from Eisai Inc., Merck, Roche, Genentech, AstraZeneca, Bayer Pharmaceuticals, AbbVie, Sanofi, Moderna, Glycotest, Exelixis and Boehringer Ingelheim, and is a member of the Data Safety Monitoring Board for Bristol-Myers Squibb. R.L. serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse Bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 Bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. R.L. has stock options in Sagimet Biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals, and is co-founder of LipoNexus Inc. R.B. received consulting fees from Novo Nordisk, Boehringer Ingelheim and GlaxoSmithKline.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}